Share-based Payment Arrangement, Expense of Insight Molecular Diagnostics Inc. from 31 Dec 2014 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Insight Molecular Diagnostics Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2014 to 30 Sep 2025.
  • Insight Molecular Diagnostics Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $521,000, a 16% increase year-over-year.
  • Insight Molecular Diagnostics Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $1,997,000, a 15% increase year-over-year.
  • Insight Molecular Diagnostics Inc. annual Share-based Payment Arrangement, Expense for 2024 was $1,753,000, a 36% decline from 2023.
  • Insight Molecular Diagnostics Inc. annual Share-based Payment Arrangement, Expense for 2023 was $2,760,000, a 73% decline from 2022.
  • Insight Molecular Diagnostics Inc. annual Share-based Payment Arrangement, Expense for 2022 was $10,042,000, a 47% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Insight Molecular Diagnostics Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $1,997,000 $521,000 +$71,000 +16% 01 Jul 2025 30 Sep 2025 10-Q 10 Nov 2025 2025 Q3
Q2 2025 $1,926,000 $504,000 +$118,000 +31% 01 Apr 2025 30 Jun 2025 10-Q 11 Aug 2025 2025 Q2
Q1 2025 $1,808,000 $473,000 +$55,000 +13% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 $1,753,000 $499,000 +$15,000 +3.1% 01 Oct 2024 31 Dec 2024 10-K 24 Mar 2025 2024 FY
Q3 2024 $1,738,000 $450,000 -$158,000 -26% 01 Jul 2024 30 Sep 2024 10-Q 10 Nov 2025 2025 Q3
Q2 2024 $1,896,000 $386,000 -$448,000 -54% 01 Apr 2024 30 Jun 2024 10-Q 11 Aug 2025 2025 Q2
Q1 2024 $2,344,000 $418,000 -$416,000 -50% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025 2025 Q1
Q4 2023 $2,760,000 $484,000 -$2,135,000 -82% 01 Oct 2023 31 Dec 2023 10-K 24 Mar 2025 2024 FY
Q3 2023 $4,895,000 $608,000 -$2,573,000 -81% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $7,468,000 $834,000 -$1,398,000 -63% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $8,866,000 $834,000 -$1,176,000 -59% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024 2024 Q1
Q4 2022 $10,042,000 $2,619,000 +$914,000 +54% 01 Oct 2022 31 Dec 2022 10-K 16 Apr 2024 2023 FY
Q3 2022 $9,128,000 $3,181,000 +$1,331,000 +72% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $7,797,000 $2,232,000 +$236,000 +12% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $7,561,000 $2,010,000 +$720,000 +56% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1
Q4 2021 $6,841,000 $1,705,000 01 Oct 2021 31 Dec 2021 10-K 12 Apr 2023 2022 FY
Q3 2021 $1,850,000 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $1,996,000 01 Apr 2021 30 Jun 2021 10-Q 12 Aug 2022 2022 Q2
Q1 2021 $1,290,000 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1
Q1 2019 $101,000 -$245,000 -71% 01 Jan 2019 31 Mar 2019 10-Q 14 May 2019 2019 Q1
Q3 2018 $1,553,000 $345,000 -$117,000 -25% 01 Jul 2018 30 Sep 2018 10-Q 13 Nov 2018 2018 Q3
Q2 2018 $1,670,000 $390,000 +$44,000 +13% 01 Apr 2018 30 Jun 2018 10-Q 14 Aug 2018 2018 Q2
Q1 2018 $1,626,000 $346,000 -$4,000 -1.1% 01 Jan 2018 31 Mar 2018 10-Q 15 May 2018 2018 Q1
Q4 2017 $1,630,000 $472,000 01 Oct 2017 31 Dec 2017 10-K 02 Apr 2018 2017 FY
Q3 2017 $462,000 +$204,000 +79% 01 Jul 2017 30 Sep 2017 10-Q 13 Nov 2018 2018 Q3
Q2 2017 $346,000 01 Apr 2017 30 Jun 2017 10-Q 14 Aug 2018 2018 Q2
Q1 2017 $350,000 +$225,000 +180% 01 Jan 2017 31 Mar 2017 10-Q 15 May 2018 2018 Q1
Q3 2016 $258,000 -$423,000 -62% 01 Jul 2016 30 Sep 2016 10-Q 10 Nov 2016 2016 Q3
Q1 2016 $125,000 -$91,000 -42% 01 Jan 2016 31 Mar 2016 10-Q 28 Apr 2017 2017 Q1
Q3 2015 $681,000 01 Jul 2015 30 Sep 2015 10-Q 10 Nov 2016 2016 Q3
Q1 2015 $216,000 01 Jan 2015 31 Mar 2015 10-Q 16 May 2016 2016 Q1

Insight Molecular Diagnostics Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $1,753,000 -$1,007,000 -36% 01 Jan 2024 31 Dec 2024 10-K 24 Mar 2025 2024 FY
2023 $2,760,000 -$7,282,000 -73% 01 Jan 2023 31 Dec 2023 10-K 24 Mar 2025 2024 FY
2022 $10,042,000 +$3,201,000 +47% 01 Jan 2022 31 Dec 2022 10-K 16 Apr 2024 2023 FY
2021 $6,841,000 +$1,775,000 +35% 01 Jan 2021 31 Dec 2021 10-K 12 Apr 2023 2022 FY
2020 $5,066,000 01 Jan 2020 31 Dec 2020 10-K 11 Mar 2022 2021 FY
2017 $1,630,000 +$708,000 +77% 01 Jan 2017 31 Dec 2017 10-K 02 Apr 2018 2017 FY
2016 $922,000 -$893,000 -49% 01 Jan 2016 31 Dec 2016 10-K 02 Apr 2018 2017 FY
2015 $1,815,000 +$1,497,000 +471% 01 Jan 2015 31 Dec 2015 10-K 02 Apr 2018 2017 FY
2014 $318,000 01 Jan 2014 31 Dec 2014 10-K 27 Feb 2017 2016 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.